Significantly elevated concentrations of serum FSCN1 have been described in head and neck cancer (HNC) patients (18) and in non-small cell lung cancer (NSCLC) patients (14, 19) compared with healthy controls. This evidence concerns the gene FSCN1 and non-small cell lung carcinoma.